Basel

Scientific Programme

The Academy day will have a range of educational symposia covering many different topics and will include interactive sessions. The main scientific programme will once again include new topics and new to ISBT speakers.

The plenary sessions will include ‘bridging the gap’ - looking at the impact of migration on transfusion medicine in Europe, ‘Big Data’ - the pros and cons of big data and big data in transfusion medicine and beyond, and the final plenary session on looking into the future with presentations on killer germs, gene therapy and ‘the Watt Worms’. The parallel sessions will be in the format regular attendees of ISBT congresses are familiar with, of one invited speaker with the remaining slots filled by orals from high scoring abstracts. The parallel sessions will cover the whole transfusion supply chain as well as sessions on challenges in resource limited settings.

The programme will include transfusion practitioner sessions, a young professional session and workshops. The scientific programme with invited speakers and topics will be available online the beginning of November. 

Programme per day

09.00-11.00 Innovation in Austria
09.00-09.30 Sound of Music: Quantum mechanics of innovation in Austria
C. Gabriel (Austria)
09.30-10.00 Innovation in cellular therapy: hype and hope
N. Worel (Austria)
10.00-10.30 Influence of Anemia on Outcome in Patients Undergoing Orthotopic Liver Transplantation" 
D. Baron (Austria)
10.30-11.00 Coffee break

11.00-13.30

Innovation in France
11.00-11.30 Transfusion medicine for sickle cell patients : from blood donor accrual to gene therapy
F. Pirenne (France)
11.30-12.00 Developpement of novel CAR-T cell approaches 
C. Ferrand (France)
12.00-12.30 Transfusion in the acute bleeding setting: massive transfusion protocols, introducing new « old” blood products such as whole blood
S. Ausset (France)
12.30-13.30 Lunch break
13.30-15.30 Innovation in Germany
13.30-14.00 TBA
14.00-14.30 Mesenchymal stromal cells for regenerative therapy
H. Schrezenmeier (Germany)
14.30-15.00 Invisible Megakaryocytes from iPSC
C. Figueiredo (Germany)
15.00-15.30 Coffee break
15.30-17.00 Innovation in Switzerland
15.30-16.00 We are stardust - what comets tell us about our origins
K. Altwegg (Switzerland)
16.00-16.30 The Sky’s the Limit - Next Generation Engineered Cellular Therapies
L. Jeker (Switzerland)
16.30-17.00 Cell-free nucleic acids in transfusion medicine
S. Waldvogel (Switzerland)
 

 

 

09.00-10.30 Various facets of donor management
09.00-09.30 Impact of blood donation on exercise tolerance
J. Helge (Denmark)
09.30-10.00 How does deferral impact the blood donor?
T. Davidson (Australia)
10.00-10.30 The gift of life - does it apply to donation for research?
V. Raivola (Finland)
09.00-10.30 Transfusion challenges in patients with sickle cell disease
09.00-09.30 Immunohaematological features of patients with sickle cell disease
V. Thornier (France)
09.30-10.00 Phenotype and allele matching: how far should we go?
C. Folman (The Netherlands)
10.00-10.30 Management of delayed hemolytic transfusion reactions and hyperhemolysis syndrome
S. Trompeter (United Kingdom)
10.30-11.00 Coffee break
11.00-12.30 Artificial Intelligence and Ethics
11.00-11.45 The use of artificial intelligence to improve health care; what's in it for transfusion medicine?
B. Geerts (The Netherlands)
11.45-12.30 Incentives and Inducements - where to draw the line?
P. Flanagan (New Zealand)
11.00-12.30 Issues around transfusion in infants and children
11.00-11.30 Platelet transfusion triggers in neonates
E. Lopriore (The Netherlands)
11.30-12.00 Diagnosing TACO in infants and children
F. Gauvin (Canada)
12.00-12.30 Applying PBM principles in paediatric patients
G. Crighton (Australia)
12.30-13.30 Lunch and Satellite Symposia
13.30-15.00 Management of transfusion-transmitted infections
13.30-14.00 Risk based decision making framework for blood safety: what's the case for ZIKA?
E. Bloch (USA)
14.00-14.30 Screening strategies to minimize the risk of TT-HEV infections
T. Vollmer (Germany)
14.30-15.00 Update on pathogen inactivation technology
M. Lozano (Spain)
13.30-15.00 Immunohaematology
13.30-14.00 PP1PK: blood group system with an identity crisis
A. Hellberg (Sweden)
14.00-14.30 Why are the GATA and KLF regulator genes included in the Blood Group tables?
N. Nogues (Spain)
14.30-15.00 Cell free fetal DNA for fetal blood group genotyping: non-invasive prenatal testing
F. Clausen (Denmark)
15.00-15.30 Coffee break
15.30-17.00 Novel technologies for transfusion medicine
15.30-16.00 IT in blood banks, present and future. A Nordic perspective
H. G. Jensen (Denmark)
16.00-16.30 Applying drones for blood supply to remote areas. Rwanda experience
S. Gatare (Rwanda)
16.30-17.00 Novel challenges in blood inventory management and bedside transfusion
L. Lodge (United Kingdom)
15.30-17.00 Platelet and Granulocyte immunology
15.30-16.00 Work-up in case of granulocyte antibodies
B. Flesch (Germany)
16.00-16.30 Optimal algorithms for serological and molecular typing in platelet alloantibodies
M. T. Ahlen (Norway)
16.30-17.00 Molecular basis of granulocyte antigens: what about HNA-2a
B. Bayat (Germany)
17.30-18.30 Opening Ceremony
18.30-21.00 Welcome Reception
07.00-08.15 Young Professionals Breakfast Session
08.30-10.00 Workshop 
08.30-10.00 Fundamentals of Good Grant Writing
I. Bates (United Kingdom)
08.30-10.00 Donors and Donation
08.30.10.00 Reach and retain donors in resource poor settings
L. Indermühle (Switzerland)
08.30-10.00 Adverse Events
08.30-09.00 Metagenomics and blood-derived products
O. Preynat-Seauve (Switzerland)
09.00-10.00 Selected abstracts
08.30-10.00 Clinical
08.30-10.00 Selected abstracts
08.30-10.00 Blood products
08.30-09.00 Benefits of thawed plasma in blood supply management
J. Zwaginga (The Netherlands)
09.00-10.00 Selected abstracts
08.30-10.00 Immunobiology of Blood Cells - Joint session with AABB
08.30-09.00 Pheno and Genotype in blood group typing - two sides of the coin - Part I
C. Westhoff (USA)
09.00-09.30 Pheno and Genotype in blood group typing - two sides of the coin - Part II
C. Gassner (Switzerland)
09.30-10.00 TBA
10.00-10.30 Coffee break

 

 

10.30-12.00 Plenary Session I: Bridging the gap
10.30-11.00 Transfusion and Treatment of severe anaemia in African Children Trial (TRACT)
K. Maitland (United Kingdom)
11.00-11.30 Global perspective of ethics in health supply - critical appraisal
S. Hurst Majno (Switzerland)
11.30-12.00 Transfusion in limited infrastructure locations
A. Greinacher (Germany)
12.00-14.00 Lunch break and Satellite Symposia
14.00-15.30 Donors and Donation
14.00-14.30 Incentives for blood donors: donor return rate among compensated and non-compensated blood donors
H. Klüter (Germany)
14.30-15.30 Selected abstracts
14.00-15.30 Adverse Events
14.00-14.30 TTI and patients with immune deficiency: selected blood products or close monitoring
H. Hirsch (Switzerland)
14.30-15.30 Selected abstracts
14.00-15.30 Clinical
14.00-14.30 ITP treatment in paediatric patients
S. Holzhauer (Germany)
14.30-15.30 Selected abstracts
14.00-15.30 Young Investigators Session
14.00-15.30 Selected abstracts
14.00-15.30 Immunobiology of Blood Cells
14.00-14.30 HLA- and Bloodgroup-Typing with NGS - One-stop shop
A. Franke (Germany)
14.30-15.30 Selected abstracts
14.00-15.30 Transfusion Practitioner session
  Anaemia management - The importance of the Transfusion Practitioner in the multidisciplinary team
14.00-14.20 The importance of anaemia management and impact in the health care setting
A. Mo
14.20-15.00 Anaemia assessment & management: the TP's role - processes, tips and resources for creating change
R. Moss & L. Bielby
15.00-15.30 Panel Discussion
L. Bielby, R. Moss, C. So-Osman, A. Mo
15.30-16.00 Coffee break

 

16.00-17.30 Donors and Donations
16.00-16.30 Blood donation and iron loss, what are the implications?
M. Van Kraaij (The Netherlands)
16.30-17.30 Selected abstracts
16.00-17.30 Adverse Events
16.00-16.30 Ending AIDS in Africa - vision or illusion?
N. Labhardt (Switzerland)
16.30-17.30 Selected abstracts
16.00-17.30 Clinical
16.00-16.30 Long term erythrocyte exchanges in SCD: when should we stop
K. Yazdanbakhsh (USA)
16.30-17.00 Treatment of thalassaemia 
Y. Aydinok (Turkey)
16.30-17.30 Selected abstracts
16.00-17.30 Management and Organisation
16.00-16.30 Management of blood supply in a country with long distances
M. Syrjala (Finland)
16.30-17.30 Selected abstracts
16.00-17.30 Immunobiology of blood cells
16.00-16.30 Innate immunity and immune haemolytic anaemia
S. Zeerleder (Switzerland, the Netherlands)
16.30-17.00 Understanding erythrocyte clearance
P. Buffet (France)
17.00-17.30 TBA
R. Rigano (Italy)
08.30-09.00 Workshop 
08.30-09.00 How to improve your scientific writing
B. van der Laaken (The Netherlands)

08.30-10.00

Donors and Donation

08.30-09.00

Current opinion in donor health – personalised donor care
C. Erikstrup (Denmark)

09.00-10.00

Selected abstracts

08.30-10.00

Adverse Events

08.30-09.00

Approaches to control infections in various settings
M. Nübling (Germany)

09.00-10.00

Selected abstracts

08.30-10.00

Clinical

08.30-09.00

An update on Patient Blood Management
K. Pavenski (Canada)

09.00-10.00

Selected abstracts

08.30-10.00

Immunobiology of blood cells

08.30-09.00

Detection of platelet auto antibodies to identify ITP state of the art
M. de Haas (The Netherlands)

09.00-10.00

Selected abstracts

10.00-10.30

Coffee break

10.30-12.00 Plenary Session II: Big Data
10.30-11.00 The 100,000 Genome project: How big data help patients with rare diseases (.... and rare blood groups)
W. Ouwehand (United Kingdom)
11.00-11.30 Molecular Genetics to Genomics 
F. Yamamoto (Spain)
11.30-12.00 Methodological considerations for big data approaches to transfusion medicine research
N. Roubinian (USA)
12.00-14.00 Lunch break and Satellite Symposia
14.00-15.30 Donors and Donation
14.00-15.30 Selected abstracts
14.00-15.30 Adverse Events
14.00-14.30 Update on TRALI/TACO and TAD (AABB pre meeting)
A. Vlaar (The Netherlands)
14.30-15.00 Iron overload from transfusion and impact on transplant outcomes
E. Angelucci (Italy)
15.00-15.30 Impact of blood donor sex on recipient outcomes
R. Middelburg (The Netherlands)
14.00-15.30 Clinical
14.00-14.30 An update on Anti platelet agents
D. Cox (Ireland)
14.30-15.00 Platelet function measurements in transfusion medicine
P. Fontana (France)
15.00-15.30 Selected abstracts
14.00-15.30 Management and Organisation - Challenges in resource-limited settings
14.00-14.30 Challenges of blood component therapy in Sub-Sahara Africa
J. Mulenga (Zambia)  
14.30-15.00 Challenges of clinical trials in resource limited settings
A. Kambugu (Uganda)

15.00-15.30

Toward an appropriate pathogen reduction technology for whole blood in resource-limited settings:
clinical development plans for the intercept blood system for whole blood
S. Amar (Switzerland)

14.00-15.30 Immunobiology of blood cells
14.00-15.30 Selected abstracts
14.00-15.30 Transfusion Practitioner Networking session
15.30-16.00 Coffee break
16.00-17.30 Donors and Donations
16.00-16.30 Moving towards voluntary non-remunerated blood donation in the Baltic States:
a common starting point does not guarantee the same results
R. Kullaste (Estonia)
16.30-17.30 Selected abstracts
16.00-17.30 Adverse Events
16.00-17.30 Selected abstracts
16.00-17.30 Cellular Therapies
16.00-16.30 Cellular therapies in the age of CRISPR-Cas
T. Cathomen (Germany)
16.30-17.00 Tumour specific cellular therapies
C. Arber (Switzerland)
17.00-17.30 T Cell Cellular therapies
M. Wolkers (The Netherlands)
16.00-17.30 Immunobiology of Blood Cells
16.00-16.30 HLA in blood transfusion
Z. Grubic (Croatia)
16.30-17.30 Selected abstracts
17.30-18.30 Poster Session
19.30-23.00 Congress party
08.30-10.00 Workshop
08.30-10.00 Present your research idea to a panel of experts
H. Ullum (Sweden)
08.30-10.00 Donors and Donation
08.30-09.00 Keeping the blood flowing
L. Eberhart (Austria)
09.00-10.00 Selected abstracts
08.30-10.00 Adverse Events
08.30-09.00 Impact of pathogen inactivation on platelet survival and alloimmunization
A. Buser (Switzerland)
09.00-10.00 Selected abstracts
08.30-10.00 Clinical
08.30-09.00 The importance and the approach to set up a system of hemovigilance
T. Aung (Myanmar)
09.00-10.00 Selected abstracts
08.30-10.00 Immunobiology of Blood Cells
08.30-09.00 Recipient factors influencing red blood cell alloimmunization
J. Hendrickson (USA)
09.00-10.00 Selected abstracts
10.00-10.30 Coffee break

 

 

10.30-12.00 Plenary session III: A Glimpse of the Future
10.30-11.00 Invisible organs
R. Blasczyk (Germany)
11.00-11.30 Gene editing in sickle cell disease
D. Bauer (USA)
11.30-12.00 The Watt Worms - take a deep breath
F. Zal (France)
  Closing Ceremony
  Farewell Lunch